EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Search
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
A global production network against supply shortages
The production of medicines is a complex process. We use our global production network to respond to increasing demand.
Understanding the language of dogs
Dogs are our best friends - however, communicating with them is not always easy. Let’s bust a few myths about our four-legged friends and how we can interact with them.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Digital innovation: „We change the way labs work“
QUDA – an in-house software – changes the way labs work. It increases our quality assurance and our drug saftey.
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
More Stories
World Rabies Day - More Stories
TreatmentSequencing
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Pyramid® / Presponse®
The pyramid®/presponse® family of vaccines provides broad coverage for BVD types 1 and 2, IBR, BRSV, PI3 and Mannheimia haemolytica with only a single dose.
Social Media Data Privacy and Cookies Statement
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Telemedicine – the standalone study that became the new normal
Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
Hypertension
Click here for more information on Hypertension
Rabisin® / Raboral V-RG®
Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Thelaziosis dog eyeworms
Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
BI X colleague about working with purpose
Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.